The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.
US-based gene therapy developer Akouos went public on Friday in an initial public offering sized at approximately $213m, scoring exits for pharmaceutical firm Novartis and health system manager Partners HealthCare.
The company priced 12.5 million shares at $17.00 each, increasing the number of shares in the offering from 8.3 million and pricing them above the offering’s $14 to $16 range. The numbers are virtually identical to those of another life sciences company, Fusion Pharma, which floated the same…
